ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP80-23 Blue Cross Response to Medical Oncology Drug Shortage of Cisplatin and Carboplatin
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါအီးကထိဘၢၣ် 11, 2023
တၢ်ဃုသ့ၣ်ညါတၢ်အစၢ
တၢ်ပာ်ဖျါ 2251 - 2260 လၢ 4034 အစၢတဖၣ်အကျါ
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP81-23 Update: Medical Drug Update for Tofersen (Qalsody), Delandistrogene Moxeparvovec (Elevidys), and Donislecel (Lantidra)
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါအီးကထိဘၢၣ် 11, 2023
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP82-23 Commercial Pharmacy Benefit Exclusion for Beyfortus™, Daxxify®, Izervay™, and Veopoz™
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါအီးကထိဘၢၣ် 11, 2023
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP83-23 Commercial Pharmacy Benefit Exclusion for Budesonide-Formoterol Aerosol Inhaler and Tiotropium Bromide Inhalation Capsule
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါအီးကထိဘၢၣ် 11, 2023
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP84-23 Commercial Pharmacy Benefit Update: Revised Drug-Related Prior Authorization (PA) Requirement Notification, Effective December 1, 2023
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါအီးကထိဘၢၣ် 11, 2023
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP85-23 MHCP Pharmacy Benefit Exclusion for Beyfortus™, Daxxify®, Elrexfio™, Izervay™, Talvey™, and Veopoz™
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါအီးကထိဘၢၣ် 11, 2023
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP86-23 MHCP Pharmacy Benefit Update: New and Revised Drug-Related Prior Authorization (PA) Requirement Notification, Effective November 1, 2023
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါအီးကထိဘၢၣ် 11, 2023
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP87-23 Availity Essentials Updated Claim Entry Forms
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါအီးကထိဘၢၣ် 11, 2023
ကသံၣ်ထံလဲ ဒီး ကသံၣ်ကျး
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
policyii-174-med-drug-eval-process-list-2023-1001.pdf